Premium
Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and Architect assays
Author(s) -
Zhou B.,
Liu M.,
Lv G.,
Zheng H.,
Wang Y.,
Sun J.,
Hou J.
Publication year - 2013
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12044
Subject(s) - antigen , immunology , microbiology and biotechnology , computational biology , medicine , biology
Summary Quantification of hepatitis B surface antigen ( HB sAg) and hepatitis B e antigen ( HB eAg) and their change model during treatment are emerging as a useful tool for assessing the outcome of hepatitis B virus ( HBV ) infection and predicting the efficacy of antiviral therapy. The aim of this study was to compare the performance of the E lecsys and A rchitect assays for HB sAg and HB eAg quantification. Quantification of HB sAg and HB eAg, determined by these two assays, were assessed in 1292 sera from patients with chronic hepatitis B(CHB). HB eAg quantification in serum was performed by calibrating the results through HB eAg P aul‐ E hrlich international ( PEI ) reference standard. The HBV genotype was determined by direct sequencing and phylogenetic analysis. Of 1292 samples, the distribution of genotype was 514 (39.78%) genotype B, 776 (60.06%) genotype C, 2 (0.16%) genotype D. The results of HB sAg and HB eAg quantification between the A rchitect and E lecsys assays were significantly correlated ( HB sAg: r = 0.939; HB eAg: r = 0.987), independent of HBV genotype and treatment phase. The mean differences between the two methods (the log 10 [ E lecsys] ‐ the log 10 [ A rchitect]) were 0.075 log 10 IU/mL and −0.149 log 10 PE IU/mL in quantifying HB sAg and HB eAg, respectively. This study demonstrates a high correlation between the E lecsys and the A rchitect assays in quantifying HB sAg and HB eAg, regardless of HBV genotype. Both the two assays can be used to monitor the HB sAg and HB eAg levels in patients with chronic hepatitis B.